Celltrion Q1 2026 Strong Results, Enhanced Shareholder Returns via Share Cancellation and Dividend

Q1 2026 consolidated sales 1.14 trillion won, operating profit 321.9 billion won, net profit 346.1 billion won (controlling)
R&D expense 122.4 billion won (10.69% of sales); biosimilar and ADC new drug pipeline progressing
Share cancellation: 9.11 million shares canceled on Apr 1; additional 488,977 shares canceled on May 6
Dividend: 750 won cash dividend for FY2025, target payout ratio 30% of EBITDA-CAPEX
Key contracts: CMO with Eli Lilly 678.7 billion won, with global pharma 294.9 billion won
Production expansion: 4th & 5th plants (180kL) with 1.23 trillion won investment
US Branchburg plant acquisition completed, CDMO business expansion
Litigation: Appeal ongoing with Humasis (claim 182.3 billion won, counterclaim 121.5 billion won)
Major shareholders: Celltrion Holdings (24.69%), NPS (6.89%)

ADVERTISEMENT (250px+)